Keynote Speaker

Juan Enriquez

Co-founder, Synthetic Genomics Inc.; Managing Director, Excel Venture Management; Co-author, Evolving Ourselves

Juan Enriquez is an active investor in early-stage private companies in the life sciences sector and is one of the world's leading authorities on the uses and benefits of genomic research. In addition to his entrepreneurial work in the life sciences, Juan writes and speaks engagingly about the profound changes that genomics and other life sciences will cause in business, technology, politics and society. His work has appeared in the *Harvard Business Review, Foreign Policy, Science, and The New York Times.*

PROGRAM TOPICS

Fireside Chat: What's New in China

China is one of the most exciting new frontiers. In a lively Q&A, a veteran of the China lifesciences industry will offer insights about doing deals with Chinese investors – buyers and partners, challenges and pitfalls, and how to achieve a win-win outcome.

From the Swamp to the Bay: What the New Administration Means for MedTech

Every new administration seeks to make its mark on the federal bureaucracy. But to what

FEATURED PANELISTS

Nicholas Galli, *Senior Director, Business Development*, Denali Therapeutics

Bruce Leuchter, M.D., *Managing Director*, PJT Partners

Henry Ma, *Senior Counsel, US Pharmaceutical, Manufacturer Relationships and Private Label*, McKesson Corporation

Kevin Marks, *Vice President, General Counsel*, Roche Molecular Systems

Steven Pollack, Ph.D., *Research Scientist,* Carbon Life Sciences; former

extent does top-down policy-making actually affect what agencies do? Leading up to the nomination of Scott Gottlieb as the new FDA Commissioner, several of the rumored contenders for Commissioner embraced relaxing regulatory standards for approval of drugs, including even eliminating the effectiveness standard and “letting the market decide." This panel will explore the prospect for significant changes to FDA’s approval processes for MedTech, and what those changes could mean for investors, innovators and patients.

Innovation and the Pricing Puzzle

Both start-ups and innovative mature players in the market are facing a sea change in U.S., EU and Asian pricing regimes. A very exciting mix of speakers will provide targeted insights into how to assess likely approvals based in part on reimbursement regimes, how to evaluate new research opportunities in limited patient markets, and where it is most likely that new reimbursement regimes will cut back on traditional research and revenue sectors.

Beyond Brexit: Navigating the Changing EU Landscape

While Brexit may steal headlines, other major changes are coming in the EU that require investment and regulatory examination: medical device regulation and enforcement will be upended by a new regime; member states are flexing their pricing muscles with joint initiatives; regulators are cracking down on data breaches; and clinical trial and IP secrecy will be strongly affected by ongoing transparency initiatives, the roll out of the General Data Protection Regulation and the first Privacy Shield review. Industry insiders will explore what these coming changes will

Director, Office of Science and Engineering Laboratories, CDRH/FDA

George Savage, M.D., *Co-Founder, Chief Medical Officer,* Proteus Digital Health

James Stansel, *Executive Vice President and General Counsel,* Pharmaceutical Research and Manufacturers of America

Lauren Sullivan, former *Vice President, Associate General Counsel, Head of Alliance Management*, Medivation, Inc.

Richard Wilder, *Associate General Counsel*, Bill & Melinda Gates Foundation

W. Vincent Xiang, Ph.D., *Partner,* Frontline BioVentures

Additional panelists to be confirmed.

mean for companies doing business in the EU.

Collision Theory: Conditions for Successful Business Combinations

Successfully combining, or collaborating, between two businesses is challenging. Whether through acquisition or partnering, creating something greater than the sum of those parts is more challenging still. This panel explores how deal architecture, communications, organizational process and company cultures can intersect to secure, or doom, an acquisition or partnership.

Sidley Austin LLP, 555 California Street, San Francisco, CA 94104